| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac409458365ff9d5dc07bf78b39ea951 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
2015-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18065785d6dcc4dda215cd0ef1453cfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88dc4ba2ae4d722b755c65ae7da5bae3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f348239a53aee36918562afa5d46ede6 |
| publicationDate |
2021-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3858376-A1 |
| titleOfInvention |
Dystrophin gene exon deletion using engineered nucleases |
| abstract |
The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a method of treating a patient with Duchenne Muscular Dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases. |
| priorityDate |
2014-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |